At 3.07billionin2013,the3Dprintingindustrywasprojectedtoreach12.8 billion in 2018 and exceed 21billionby2020(WohlersandCaffrey,2013).Alucrativepartofthisexpandingindustryincludesprintingbiocompatiblemedicalimplants,devices,andtissuescaffolds.Acommonproblemencounteredwithtraditionaldevices,implants,andtissuescaffoldsisthattheyarenotuniquetothepatientandlackthenecessarystrengthandbiocompatibility.Toanswerthesedemands,customizabledevicesarebeingproducedfrompatientmedicalscansandCADdesignsusing3Dprinters.Theseprinterstraditionallyusethermoplasticsbecauseoftheeasewithwhichtheyareprinted.Theseplasticsaretypicallyregardedasbiocompatiblebutcandegradetolessbiocompatibleformsinthebodyandleavetheimplantsite,causinginflammatoryandforeignbodyresponses.Becauseoftheseproblems,therehasbeenafocusondevelopingnewbiomaterialsformedical3Dprinters.SpidersilkisanaturalproteinpolymerthatisstrongerthansteelorKevlarandmoreelasticthannylon.Ithasalsobeenshowntobemorebiocompatiblethanmanymaterialscurrentlyusedin3Dprinters.Inpreviousanimalstudies,spidersilkhasproventonotcauseaninflammatoryresponseupondegradationwhichmakesitadesiredresorbableimplantmaterial(Lewis,2006).A3Dprintersystemcomprisedofasyntheticspidersilkresinandamodified3Dprinterwasdeveloped.Afusedfilament3Dprinter,purchasedforunder600, was modified with a custom syringe pump design. This syringe pump allowed for the extrusion of spider silk proteins through a needle, producing defined structures. Cell studies were performed on these structures which showed favorable cell attachment and growth. Capable of entering various emerging industries, spider silk offers an alternative in 3D printed biomaterials